Cadila Healthcare’s Zydus Cadila has received final approval from the US health regulator to market Candesartan Cilexetil and Hydrochlorothiazide tablets formulations used in treating high blood pressure. The approval by the US Food and Drug Administration (USFDA) is for multiple Candesartan Cilexetil and hydrochlorothiazide tablets of 16 mg/12.5 mg, 32 mg/12.5 mg, and 32 mg/25 mg.

The drug is used to treat high blood pressure. Lowering blood pressure helps prevent strokes, heart attacks, and kidney problems. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group has now more than 175 approvals and has so far filed 310 abbreviated new drug application (ANDAs) since the commencement of the filing process in FY2003-04.

10 Diagnostic Imaging Trends for 2018



Digital version